poly(A) specific ribonuclease subunit PAN2Genealiases: DEDCRF · USP52
Q-omics provides the consensus-scored PAN2 profile across patient tissues and cancer cell-line models. PAN2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PAN2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PAN2 RNA expression shows 20,794 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KIRC, and UVM as cancer lineages where PAN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAN2 survival associations across molecular data types. PAN2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAN2 RNA expression–survival associations across cancer types. High PAN2 expression shows unfavorable associations in LGG, COAD, KICH and UVM, but favorable associations in UCS and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PAN2 RNA expression.
This table summarizes PAN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAN2 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, COAD, BLCA and HNSC. The KIRC box plot shows higher PAN2 RNA expression in tumor versus normal tissue (log2 FC = +0.554, t-test p < 0.001).
This table shows molecular features associated with PAN2 in patient tissues and cancer cell lines. In patient samples, PAN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
